Anaphylaxis after administration of ibritumomab tiuxetan for follicular non-hodgkin lymphoma.
We report an anaphylactic reaction in a 45-year-old gentleman with an 8-year history of extensively treated, relapsing follicular lymphoma who was receiving a second treatment with ibritumomab tiuxetan. Within seconds of receiving Y-90 ibritumomab, he developed chest tightness, shallow respirations, hypotension, and incontinence. After successful resuscitation, a human antimouse antibody (HAMA) level was found to be elevated, 618 ng/mL (reference 0-188 ng/mL).
Jankowitz
Rachel
R
UPMC Cancer Centers, UPMC Cancer Pavilion, Pittsburgh, Pennsylvania, USA.
Joyce
Judith
J
Jacobs
Samuel A
SA
D000707:Anaphylaxis / Q000139:chemically induced*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D008224:Lymphoma, Follicular / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D016499:Radioimmunotherapy / Q000379:methods; D015021:Yttrium Radioisotopes / Q000009:adverse effects
D000911:Antibodies, Monoclonal; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan